1. Home
  2. HAIN vs GANX Comparison

HAIN vs GANX Comparison

Compare HAIN & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hain Celestial Group Inc. (The)

HAIN

Hain Celestial Group Inc. (The)

HOLD

Current Price

$0.74

Market Cap

70.2M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.59

Market Cap

78.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAIN
GANX
Founded
1993
2017
Country
United States
United States
Employees
2600
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.2M
78.2M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
HAIN
GANX
Price
$0.74
$1.59
Analyst Decision
Hold
Strong Buy
Analyst Count
9
4
Target Price
$2.23
$7.50
AVG Volume (30 Days)
1.1M
485.7K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
31.46
EPS
N/A
N/A
Revenue
$2,457,769,000.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$1.41
52 Week High
$2.08
$4.34

Technical Indicators

Market Signals
Indicator
HAIN
GANX
Relative Strength Index (RSI) 47.33 32.36
Support Level $0.58 N/A
Resistance Level $0.82 $2.09
Average True Range (ATR) 0.08 0.10
MACD 0.00 -0.02
Stochastic Oscillator 59.48 14.29

Price Performance

Historical Comparison
HAIN
GANX

About HAIN Hain Celestial Group Inc. (The)

The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: